Despite achieving its highest quarterly revenue, Rossari Biotech Ltd (BOM:543213) faces challenges with declining EBITDA margins and geopolitical uncertainties.

Rossari Biotech reported a 33.43% year-on-year rise in Q4FY26 net profit to ₹46 crore, supported by 18.2% revenue growth to ...

ICICI Direct is bullish on Rossari Biotech recommended buy rating on the stock with a target price of Rs 570 in its research ...

For the full year,net profit rose 9.41% to Rs 149.21 crore in the year ended March 2026 as against Rs 136.38 crore during the previous year ended March 2025. Sales rose 15.19% to Rs 2396.37 crore in ...

The company has set up a new Research and Development Facility at Navi Mumbai located at Ellora Olearise, A-786, 06th Floor, Khairane MIDC, Koparkhairane, Navi Mumbai - 400 710.

The average one-year price target for Rossari Biotech (BSE:543213) has been revised to ₹ 652.81 / share. This is a decrease of 21.25% from the prior estimate of ₹ 828.92 dated December 20, 2025. The ...

The average one-year price target for Rossari Biotech (NSEI:ROSSARI) has been revised to ₹ 648.21 / share. This is a decrease of 21.79% from the prior estimate of ₹ 828.85 dated January 11, 2026. The ...

Rossari Biotech Limited informed the Exchange regarding Press Release dated April 27, 2026 titled " Rossari Biotech announces Q4 FY 26 results". View a ...

Stocks like Coal India, Phoenix Mills, Punjab and Sind Bank, Adani Total Gas, Rallis India, Jindal Saw, Rossari Biotech, City ...

Analyst / Investor Meet - Intimation - Rediff MoneyWiz, the personal finance service from Rediff.com equips the user with tools and information in the form of graphs, charts, expert advice, and more ...